Elicio Therapeutics Reports $10.6 Million Net Loss in Q2 2025, Focuses on ELI-002 7P Development

Elicio Therapeutics, Inc. reported a net loss of $10.6 million for the second quarter of 2025, compared to a loss of $7.2 million in the same period of 2024. For the first half of 2025, the company recorded a net loss of $21.8 million, up from $19.1 million in the prior year. The increase in losses is attributed to higher general and administrative expenses, which rose to $3.1 million in Q2 2025 from $2.7 million in Q2 2024, primarily due to increased professional fees related to financing activities. Research and development expenses decreased to $7.0 million in Q2 2025 from $8.2 million in Q2 2024, reflecting reduced clinical trial manufacturing costs as the company advanced its lead product candidate, ELI-002 7P.

Elicio's total operating expenses for the second quarter of 2025 were $10.1 million, a decrease from $10.9 million in the same quarter of the previous year. The company reported a total of $22.1 million in cash and cash equivalents as of June 30, 2025, an increase from $17.6 million at the end of 2024. This increase was primarily due to financing activities, including proceeds from the issuance of common stock and warrants, which totaled approximately $22.3 million for the first half of 2025. The company’s accumulated deficit reached $215.9 million as of June 30, 2025.

In terms of strategic developments, Elicio continues to focus on its clinical pipeline, particularly the ELI-002 7P vaccine, which is currently in a Phase 2 study targeting mutant KRAS pancreatic cancer. The Independent Data Monitoring Committee recently recommended that the trial continue without modifications, confirming a favorable safety profile for the product. The company is also advancing its preclinical candidates, ELI-007 and ELI-008, which target other oncogenic mutations.

Operationally, Elicio has seen a significant increase in its employee headcount, which is expected to support its ongoing research and development efforts. The company anticipates that its cash reserves will be sufficient to fund operations into the first quarter of 2026, although it acknowledges the need for additional financing to continue its development programs. Elicio plans to address its funding needs through public offerings, private placements, and potential collaborations, but it cautions that there is no guarantee that these efforts will be successful.

Looking ahead, Elicio expects to incur substantial expenditures as it continues to develop its product candidates and seeks regulatory approvals. The company remains focused on advancing its clinical trials and expanding its pipeline, while also managing its cash flow and operational costs. The ongoing development of ELI-002 7P and other candidates will be critical to the company's future financial performance and market position.